BCAB is making big moves today, despite poor earnings last week!

Shares of BioAtla, Inc. (BCAB) are trading 17% higher at a price of $9.37 at the time of this writing. The company is outpacing peers in the biotech sector. While the stock is trading far from it's 52 week high, investors seem to sense a bargain today. 

There must be something attracting investor attention, although the catalyst at this time is not clear. This upward price move comes on the back of a poor earnings report last week.

BioAtla, Inc. has been trading between a 52-week high of $43.24 and a 52-week low of $2.01. The stock has a market cap of $340 Million.

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow it to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.